243 related articles for article (PubMed ID: 32353871)
1. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis.
Delvino P; Bartoletti A; Monti S; Biglia A; Montecucco C; Carducci M; Ripamonti G; Cavagna L
Rheumatology (Oxford); 2020 Dec; 59(12):e125-e127. PubMed ID: 32353871
[No Abstract] [Full Text] [Related]
2. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
Nousari Y; Wu BC; Valenzuela G
Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
[No Abstract] [Full Text] [Related]
3. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
[No Abstract] [Full Text] [Related]
4. Successful treatment of spondyloenchondrodysplasia with baricitinib.
Shimizu M; Inoue N; Mizuta M; Irabu H; Okajima M; Honda Y; Nihira H; Izawa K; Yachie A; Wada T
Rheumatology (Oxford); 2021 Feb; 60(2):e44-e46. PubMed ID: 32856090
[No Abstract] [Full Text] [Related]
5. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.
De Stefano L; Bobbio-Pallavicini F; Montecucco C; Bugatti S
Rheumatology (Oxford); 2022 Mar; 61(3):e64-e66. PubMed ID: 34647989
[No Abstract] [Full Text] [Related]
7. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
Valor-Méndez L; Voskens C; Rech J; Kleyer A; Schett G
Rheumatology (Oxford); 2021 Apr; 60(4):e122-e123. PubMed ID: 33141876
[No Abstract] [Full Text] [Related]
8. Repigmentation of vitiligo with oral baricitinib.
Mumford BP; Gibson A; Chong AH
Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
[No Abstract] [Full Text] [Related]
9. Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.
Han GM; Yang WS; Yang B
JAMA Dermatol; 2021 Apr; 157(4):466-468. PubMed ID: 33656520
[No Abstract] [Full Text] [Related]
10. Baricitinib: A chance to treat COVID-19?
Lo Caputo S; Corso G; Clerici M; Santantonio TA
J Med Virol; 2020 Nov; 92(11):2343-2344. PubMed ID: 32437019
[No Abstract] [Full Text] [Related]
11. Successful treatment of joint and fascial chronic graft-versus-host disease with baricitinib.
Shimizu M; Shimbo A; Takagi M; Eguchi K; Ishimura M; Sugita J; Morio T; Kanegane H
Rheumatology (Oxford); 2021 Dec; 61(1):e1-e3. PubMed ID: 34302457
[No Abstract] [Full Text] [Related]
12. Cytomegalovirus Enteritis in a Patient with Rheumatoid Arthritis Receiving Baricitinib.
Sugawara E; Matsui K; Amasaki Y
J Rheumatol; 2020 Dec; 47(12):1835-1836. PubMed ID: 33262287
[No Abstract] [Full Text] [Related]
13. An EUA for baricitinib (Olumiant) for COVID-19.
Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
[No Abstract] [Full Text] [Related]
14. Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation.
Diluvio L; Matteini E; Lambiase S; Cioni A; Gaeta Shumak R; Dattola A; Bianchi L; Campione E
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e478-e480. PubMed ID: 38084867
[No Abstract] [Full Text] [Related]
15. Massive nodulous lesions on hands and feet in a RA patient and improvement under baricitinib treatment.
Valor-Méndez L; Hagen M; Kleyer A; Manger B; Schett G
RMD Open; 2020 Nov; 6(3):. PubMed ID: 33214327
[No Abstract] [Full Text] [Related]
16. Baricitinib in Alopecia Areata.
Messenger A; Harries M
N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
[No Abstract] [Full Text] [Related]
17. Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib.
Russo G; Laffitte E
Acta Derm Venereol; 2024 Apr; 104():adv39970. PubMed ID: 38566407
[No Abstract] [Full Text] [Related]
18. Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
Hudowenz O; Klemm P; Lange U; Mueller-Ladner U
Lancet; 2021 Jan; 397(10272):409. PubMed ID: 33516339
[No Abstract] [Full Text] [Related]
19. Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib.
Magarreiro-Silva A; Pimenta R; Gouveia AI; Mendes-Bastos P
J Dtsch Dermatol Ges; 2024 May; 22(5):704-705. PubMed ID: 38470157
[No Abstract] [Full Text] [Related]
20. Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting.
d'Alessandro M; Perillo F; Metella Refini R; Bergantini L; Bellisai F; Selvi E; Cameli P; Manganelli S; Conticini E; Cantarini L; Sestini P; Frediani B; Bargagli E
Int Immunopharmacol; 2020 Sep; 86():106748. PubMed ID: 32645631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
